Dermatomyositis Flare With Immune Checkpoint Inhibitor Therapy for Melanoma

Immune checkpoint inhibitor (ICI) medications have seen expanded use in the management of numerous malignancies. These therapies encompass a unique spectrum of immune-related adverse events (irAEs). Rheumatological irAEs from ICIs have been described in various case reports; however, limited literat...

Descripción completa

Detalles Bibliográficos
Autores principales: Thomas, Rachel, Patel, Hamish, Scott, Joshua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Dermatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8106943/
https://www.ncbi.nlm.nih.gov/pubmed/33981507
http://dx.doi.org/10.7759/cureus.14387
_version_ 1783689862754336768
author Thomas, Rachel
Patel, Hamish
Scott, Joshua
author_facet Thomas, Rachel
Patel, Hamish
Scott, Joshua
author_sort Thomas, Rachel
collection PubMed
description Immune checkpoint inhibitor (ICI) medications have seen expanded use in the management of numerous malignancies. These therapies encompass a unique spectrum of immune-related adverse events (irAEs). Rheumatological irAEs from ICIs have been described in various case reports; however, limited literature exists regarding the treatment of patients with pre-existing myositis. We describe a case of myositis flare after initiation of nivolumab for metastatic melanoma in a patient who had previously achieved remission of dermatomyositis.
format Online
Article
Text
id pubmed-8106943
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-81069432021-05-11 Dermatomyositis Flare With Immune Checkpoint Inhibitor Therapy for Melanoma Thomas, Rachel Patel, Hamish Scott, Joshua Cureus Dermatology Immune checkpoint inhibitor (ICI) medications have seen expanded use in the management of numerous malignancies. These therapies encompass a unique spectrum of immune-related adverse events (irAEs). Rheumatological irAEs from ICIs have been described in various case reports; however, limited literature exists regarding the treatment of patients with pre-existing myositis. We describe a case of myositis flare after initiation of nivolumab for metastatic melanoma in a patient who had previously achieved remission of dermatomyositis. Cureus 2021-04-09 /pmc/articles/PMC8106943/ /pubmed/33981507 http://dx.doi.org/10.7759/cureus.14387 Text en Copyright © 2021, Thomas et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Dermatology
Thomas, Rachel
Patel, Hamish
Scott, Joshua
Dermatomyositis Flare With Immune Checkpoint Inhibitor Therapy for Melanoma
title Dermatomyositis Flare With Immune Checkpoint Inhibitor Therapy for Melanoma
title_full Dermatomyositis Flare With Immune Checkpoint Inhibitor Therapy for Melanoma
title_fullStr Dermatomyositis Flare With Immune Checkpoint Inhibitor Therapy for Melanoma
title_full_unstemmed Dermatomyositis Flare With Immune Checkpoint Inhibitor Therapy for Melanoma
title_short Dermatomyositis Flare With Immune Checkpoint Inhibitor Therapy for Melanoma
title_sort dermatomyositis flare with immune checkpoint inhibitor therapy for melanoma
topic Dermatology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8106943/
https://www.ncbi.nlm.nih.gov/pubmed/33981507
http://dx.doi.org/10.7759/cureus.14387
work_keys_str_mv AT thomasrachel dermatomyositisflarewithimmunecheckpointinhibitortherapyformelanoma
AT patelhamish dermatomyositisflarewithimmunecheckpointinhibitortherapyformelanoma
AT scottjoshua dermatomyositisflarewithimmunecheckpointinhibitortherapyformelanoma

Ejemplares similares